InvestorsHub Logo
Followers 8
Posts 2018
Boards Moderated 0
Alias Born 07/19/2006

Re: haysaw post# 36567

Thursday, 04/14/2011 6:21:23 PM

Thursday, April 14, 2011 6:21:23 PM

Post# of 51844
Yes, hay, but we don't know of anything about that compound and trial design. Is it purely a safety issue, phase I trial, looking only at kinetics and such, or will it also include some cognitive parameters? Are they inclined, or forced, to include Cortex into the results??? or just at deciding to enter into phase IIa?

It would seem to me the best scenario with Servier might be a decision has been made to enter into phase IIa with the Servier lead compound for the area of cognition/neurodegeneration. That would be big news for us, and would probably entice Servier to hold their nose and enter into some sort of arrangement with Cortex. Paradoxically, a Servier failure with their lead might interest them into other Cortex high ampakines. But the 'when' with Server and the 'if it's safe' are not knowns at this juncture, but it is certainly the most intriguing issue for me....
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News